VC-backed Unum Therapeutics rolls out IPO
Cambridge, Massachusetts-based Unum Therapeutics Inc, a developer of antibody-directed cellular immunotherapy, has raised $69.2 million for its IPO after pricing its 5.77 million shares at $12 per share. The stock began trading March 29, 2018 on the NASDAQ under the ticker symbol "UMRX." Morgan Stanley and Cowen are the lead underwriters. Unum's pre-IPO backers include New Leaf Venture Partners, Brace Pharma Capital, Cowen Private Investments, Novo A/S, Sabby Management LLC, Wellington Management Company LLP, Fidelity Biosciences, Atlas Venture and Sanofi-Genzyme BioVentures.
29 March 2018•2 mins read
